Enzeevu · DIN 02562510 · 2 mg/0.05 mL · injection, 0.05 mL pre-filled syringe (preservative-free)
Limited Use, Reason for Use code 729, 730, 731 requiredMarketed · checked November 18, 2026
StatusLimited Use, Reason for Use code 729, 730, 731 required
PolicyOntario biosimilar policy: Eylea available through EAP for approved exceptions; Aflivu, Yesafili available as Limited Use (OHIP bulletin 251105, transition from November 28, 2025). (ontario.ca, Updated November 21, 2025 ↗)
Write on scriptone applicable Reason for Use code, 729 or 730 or 731 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays:
• ODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
• Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Biosimilar policy source
Biosimilar versions of Eylea® (aflibercept) and Xolair® (omalizumab) were listed on the Formulary as Limited Use Benefits with the August 2025 Formulary update and biosimilar version of Actemra® (tocilizumab) was listed as a Limited Use Benefit with the May 2025 Formulary update. In accordance with this New Start Rule, ODB program recipients who are treatment-naïve will only receive coverage for the biosimilar versions of these biologics, provided that they meet the applicable Limited Use criteria for the products. (ontario.ca, Updated November 21, 2025 ↗)
ODB program recipients who are using Eylea®, Actemra®, or Xolair® during the transition period and require continued coverage of their product after the end of the transition period, must have their prescriber apply to the EAP for a medically necessary exemption. Requests for medically necessary exemptions are assessed on a case-by-case basis, and prescribers are encouraged to apply during the transition period to avoid an unintended gap in coverage.
Requests for medically necessary exemptions must include documentation that the recipient has tried up to two biosimilar versions (where applicable) and experienced an adverse effect documented on the Health Canada side effect reporting form. A copy of each completed Health Canada reporting form must be included in the EAP request.
Medically necessary exemptions will not be considered for ODB recipients subject to the New Start Rule. (ontario.ca, Updated November 21, 2025 ↗)
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 729, 730, 731
Reason for Use code 729
For the treatment of patients with neovascular (wet) age-related macular degeneration (AMD) in a treatment-naive eye.
Initial diagnosis should be confirmed by an appropriate diagnostic procedure and administration should be done by a qualified ophthalmologist experienced in intravitreal injections.
Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.
Treatment should be initiated with a monthly intravitreal injection for the first 3 consecutive doses, followed by one injection every 2 months.
The interval between two doses should not be shorter than one month.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 730
For the treatment of patients with clinically significant macular edema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO).
Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.
Treatment should be initiated with an intravitreal injection once every month. The interval between two doses should not be shorter than one month. The treatment interval may be extended up to 3 months based on visual and anatomic outcomes.
Prescribers are advised to periodically assess the need for continued therapy.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
Reason for Use code 731
For the treatment of patients with clinically significant diabetic macular edema (DME) for whom laser photocoagulation is also indicated; and a hemoglobin A1c of less than 12 percent.
Patients receiving concurrent administration of other anti-VEGF intravitreal injections are not eligible for reimbursement.
Treatment should be initiated with a monthly intravitreal injection for the first 5 consecutive doses, followed by one injection every 2 months.
The interval between two doses should not be shorter than one month.
Treatment with anti-VEGF agents should only be continued in patients who maintain adequate response to therapy.
Coverage will be provided for patients responding to therapy with another anti-VEGF agent who switch to this product. Coverage will NOT be provided for patients who have failed to respond to other anti-VEGF agents.
Coverage limit:
LU Authorization Period: 1 year
No interchangeable product listed in the Ontario extract
Enzeevu · DIN 02562510
Manufacturer: Sandoz Canada Inc.; listing date 2026-01-30
Health Canada: Marketed since 2026-02-09 · brand ENZEEVU · ATC S01LA05 AFLIBERCEPT · form Solution · route Intravitreal · ingredients AFLIBERCEPT 2 MG/0.05ML · company Sandoz canada incorporated · schedule Prescription, Schedule d
Enzeevu: Formulary list price $850.80 per unit (the source does not state the unit; exact figure $850.8000). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02562510)
Source record
DIN 02562510: Enzeevu
Raw flags: sec12=Y, sec3=Y
Item: 520000044; group id 574; item number 1527; lccId 00416; manufacturer id SDZ
Source form: Inj Sol-0.05mL Pref Syr (Preservative-Free); strength: 2mg/0.05mL
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $850.8000; ministry $850.8000
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02562510
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=106539
Shortage status: not checked (no credentials)